title: Two pregnancies shortly after transplantation with reduced intensity conditioning in chronic myeloid leukemia.
abstract: POI is a relevant late complication after HSCT and occurring more frequently after MAC than after RIC regimens. Reports on the frequency of POI after RIC in a large pediatric and adolescent population are lacking. In this study, we describe a girl affected by CML diagnosed at the age of 15 yr and treated with oncarbide and interferon followed by imatinib and dasatinib. She had two pregnancies shortly after RIC performed according to the CML-SCT I-BFM protocol including TT, FLU, and MEL. Hypergonadotropic hypogonadism occurred four months after HSCT; menstruations resumed regularly six months after HSCT. Eight and 20 months after HSCT, the patient became pregnant and then delivered, respectively, two babies at term by cesarean section. Both newborns had no neonatal complications. Donor chimerism at time of two pregnancies and five yr after transplantation demonstrated complete donor engraftment. These findings suggest that I-BFM CML-SCT protocol could be a promising treatment option for adolescents or young adults with CML eligible for HSCT.
authors.affiliation: Stem Cell Transplantation Unit - Haematology-Oncology Department, G. Gaslini Children's Research Institute, Genova, Italy.
authors.forename: Maura
authors.initials: M
authors.lastname: Faraci
authors.affiliation: Stem Cell Transplantation Unit, St Anna Children's Hospital, Vienna, Austria.
authors.forename: Susanne
authors.initials: S
authors.lastname: Matthes-Martin
authors.affiliation: Stem Cell Transplantation Unit - Haematology-Oncology Department, G. Gaslini Children's Research Institute, Genova, Italy.
authors.forename: Edoardo
authors.initials: E
authors.lastname: Lanino
authors.affiliation: Stem Cell Transplantation Unit - Haematology-Oncology Department, G. Gaslini Children's Research Institute, Genova, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Morreale
authors.affiliation: Stem Cell Transplantation Unit - Haematology-Oncology Department, G. Gaslini Children's Research Institute, Genova, Italy.
authors.forename: Marta
authors.initials: M
authors.lastname: Ferretti
authors.affiliation: Stem Cell Transplantation Unit - Haematology-Oncology Department, G. Gaslini Children's Research Institute, Genova, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Giardino
authors.affiliation: Haematology Unit - Haematology-Oncology Department, G. Gaslini Children's Research Institute, Genova, Italy.
authors.forename: Concetta
authors.initials: C
authors.lastname: Micalizzi
authors.affiliation: Clinica Pediatrica Università degli Studi di Milano Bicocca, Ospedale San Gerardo, Monza, Italy.
authors.forename: Adriana
authors.initials: A
authors.lastname: Balduzzi
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000069439:Dasatinib / Q000008:administration & dosage; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D000068877:Imatinib Mesylate / Q000008:administration & dosage; D007372:Interferons / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000628:therapy*; D011247:Pregnancy; D016649:Primary Ovarian Insufficiency / Q000517:prevention & control; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D000068877:Imatinib Mesylate; D007372:Interferons; D000069439:Dasatinib; D006918:Hydroxyurea
keywords: chronic myeloid leukemia; premature ovarian insufficiency; reduced intensity conditioning regimen